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Abstract
Background: Adding bevacizumab to chemotherapy for recurrent, persistent or metastatic cervical
cancer significantly improved overall survival (primary endpoint), progression-free survival and
overall response rate in the randomized Phase III GOG-0240 trial. However, data for bevacizumab-
containing therapy are scarce in Japanese patients with advanced cervical cancer.
Methods: The primary objective of the single-arm multicenter Phase II JO29569 study was to
evaluate the tolerability of paclitaxel (135mg/m2 over 24 h or 175mg/m2 over 3 h), cisplatin
(50mg/m2) and bevacizumab (15mg/kg), administered every 3 weeks until disease progression or
unacceptable toxicity in Japanese patients with stage IVB, persistent or recurrent cervical cancer.
Results: The seven treated patients received a median of nine (range 7–12) bevacizumab cycles
and six (range 4–12) chemotherapy cycles. None of the predefined adverse events occurred during
the tolerability evaluation period. The most common all-grade adverse events were alopecia,
hypertension, decreased appetite, nausea and peripheral sensory neuropathy. There were no
cases of fistula. The most common grade ≥3 adverse events were hypertension, neutrophil count
decreased and neutropenia. Only one patient experienced febrile neutropenia. The overall
response rate was 86% (95% confidence interval, 42–100%), including a complete response in one
patient. At data cutoff, disease had progressed in one patient; bevacizumab therapy was ongoing
in the remaining six.
Conclusions: According to the specified primary objective, a regimen of cisplatin, paclitaxel and
bevacizumab was tolerable in Japanese patients and demonstrated encouraging activity in this
small single-arm study. Further study is warranted to confirm the safety and effectiveness of beva-
cizumab in Japanese patients with cervical cancer.
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Introduction
Globally, cervical cancer is the fourth most common cancer in
women, and the seventh overall (1). In 2012 there were an estimated
528 000 new cases of cervical cancer and 266 000 deaths from this
disease, representing 7.5% of all deaths from cancer in women.
Corresponding figures specifically for Japan in 2012 were 9390 new
cases and 3645 deaths, making cervical cancer the fifth most com-
mon cancer in Japanese women after breast, colorectal, gastric and
lung cancers. The incidence of cervical cancer and associated mortal-
ity in Japan have been increasing since 1990 (2), particularly in
younger women. Among women aged <50 years, mortality from
cervical cancer has doubled during the past three decades (3).
A recently reported cancer registry study of age-specific mortality
rates from cervical cancer in the Kanagawa population indicated
increasing trends for women aged 20–29 and 30–49. The particu-
larly low rate of cervical screening in young Japanese women is
likely to contribute to this discrepancy with Western countries; fur-
thermore, proactive recommendations for human papilloma virus
vaccination have been suspended in Japan (4,5).
For patients with advanced cervical cancer, one of the most
important recent advances has been the introduction of bevacizu-
mab. This monoclonal antibody targets vascular endothelial growth
factor (VEGF), the key mediator of tumor angiogenesis.
Bevacizumab has demonstrated efficacy in a wide range of solid
tumor types, including advanced cervical cancer. In the Gynecologic
Oncology Group (GOG)-0240 randomized Phase III trial, the add-
ition of bevacizumab to chemotherapy (either cisplatin plus paclitax-
el or topotecan plus paclitaxel) for recurrent, persistent or metastatic
cervical cancer significantly improved overall survival (primary end-
point), progression-free survival (secondary endpoint) and the over-
all response rate (secondary endpoint) (6). These significant efficacy
benefits were not associated with any significant detrimental effect
of bevacizumab on health-related quality of life (7). Bevacizumab
was associated with a significantly increased incidence of grade ≥2
hypertension (25% versus 2% in patients receiving chemotherapy
alone), but no patients discontinued bevacizumab because of this
side effect. Grade ≥3 gastrointestinal and genitourinary fistulas were
also more common in patients receiving bevacizumab-containing
therapy compared with chemotherapy alone, driven by an elevated
incidence of gastrointestinal-vaginal fistulae [8.3% versus 0.9%,
respectively (8)]. However, incidences of other typical bevacizumab-
associated adverse events were similar to those reported for other
tumor types and there was no difference in the incidence of fatal
adverse events between the bevacizumab and non-bevacizumab
treatment arms.
The GOG-0240 trial was conducted predominantly in the
United States, with a small number of additional participating sites
in Spain. Data in Japanese patients treated with bevacizumab for
cervical cancer are extremely limited. Therefore, we conducted the
present single-arm study to assess the tolerability, safety and activity
of bevacizumab-containing therapy in a Japanese population of
patients with advanced cervical cancer.
Patients and methods
Study design
JO29569 was a multicenter single-arm phase II study evaluating the
combination of paclitaxel, cisplatin and bevacizumab in Japanese
patients with stage IVB, persistent or recurrent cervical cancer. The
target sample size for the study was six patients, based on the fact
that tolerability is typically evaluated in 3–6 patients per cohort in
most studies with the primary objective of evaluating the tolerability
of a given treatment.
The study protocol was approved by the Independent Review
Board of each participating site.
Patients
Eligible patients were aged ≥20 years and had GOG performance
status 0 or 1, radiologically confirmed stage IVB, persistent or recur-
rent cervical cancer that was not amenable to curative treatment
with surgery or radiation therapy (including concurrent chemora-
diotherapy), and a life expectancy of ≥3 months. Patients had to
have adequate hematologic, renal and hepatic function. Patients
were ineligible if they had received any prior chemotherapy (except
with concurrent radiation) for recurrent disease, any prior anti-
VEGF or anti-VEGF receptor therapy, prior surgery for cervical can-
cer within the preceding 4 weeks, radiation (without concurrent
chemotherapy) within the preceding 3 weeks, chemoradiation within
the preceding 6 weeks, major surgery within the preceding 4 weeks
or anticipated during the course of the study, or biopsy within
1 week before study entry. Patients were not eligible if they had:
clinical signs or symptoms of intestinal obstruction requiring paren-
teral hydration or nutrition; a serious non-healing wound, ulcer or
bone fracture; a history of abdominal fistula, gastrointestinal perfor-
ation or intra-abdominal abscess within 6 months before study
entry; bilateral hydronephrosis that could not be alleviated by
ureteral stent or percutaneous drainage; complications or history
of symptomatic cerebrovascular accident within 6 months before
study entry; ongoing grade ≥2 peripheral neuropathy according
to National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE) version 4.03; central nervous system
metastases that were symptomatic or required treatment; or compli-
cations or history of NCI CTCAE grade ≥2 hemoptysis within
1 month before study entry. Patients were also excluded if they were
considered to be at high risk of bleeding, or if they were pregnant or
nursing. All patients provided written informed consent.
Treatment
All patients received cisplatin 50mg/m2 combined with paclitaxel
given either at 135mg/m2 infused over 24 h or 175mg/m2 infused
over 3 h (choice of paclitaxel regimen at the investigator’s discre-
tion). In addition, all patients received bevacizumab 15mg/kg.
Treatment with all three agents was repeated every 3 weeks until
disease progression or unacceptable adverse events. If a patient dis-
continued chemotherapy because of an adverse event, bevacizumab
could be continued as a single agent provided the adverse event had
not been caused by bevacizumab.
Study objectives
The primary objective was to evaluate the tolerability of the bevaci-
zumab, cisplatin and paclitaxel combination in Japanese patients
with advanced or recurrent cervical cancer. The evaluation period
for tolerability was from day 1 to day 21 of cycle 1. The regimen
was considered tolerable if no more than 34% of patients evaluable
for tolerability experienced any of the following adverse events
(graded according to NCI CTCAE version 4.03) considered by the
investigator to be related to any of the study drugs: grade 4 neutro-
phil count decrease persisting for ≥7 days; febrile neutropenia; grade 4
platelet count decrease or grade 3 platelet count decrease requiring
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platelet transfusion; grade 4 hypertension; grade ≥3 diarrhea, nau-
sea, vomiting or rash that could not be controlled with appropriate
medical management; grade ≥3 liver function abnormality; or other
grade ≥3 non-hematologic toxicity, excluding transient electrolyte
abnormality. A ≥3-week delay in administration of cycle 2 because
of drug-related adverse events was also considered as a qualifying
adverse event.
Secondary objectives were to evaluate the safety (frequency,
severity and time to onset of adverse events) and efficacy (tumor
response according to Response Evaluation Criteria in Solid Tumors
[version 1.1], confirmed at least 42 days after the first recorded
response) of the triplet regimen. The following adverse events were
considered to be of special interest for bevacizumab and were
reported according to grouped preferred terms: any grade of non-
gastrointestinal fistula or abscess; any grade of gastrointestinal per-
foration; grade ≥3 bleeding; grade ≥3 congestive heart failure or left
ventricular systolic dysfunction; febrile neutropenia; grade ≥3 hyper-
tension; grade ≥3 proteinuria; any grade of arterial thromboembolic
event; grade ≥3 venous thromboembolic event; grade ≥3 wound-
healing complication; or any grade of posterior reversible encephal-
opathy syndrome. Adverse events were classified as serious adverse
events if they met any of the following criteria: fatal; life threatening;
requiring or prolonging inpatient hospitalization; resulting in per-
sistent or significant disability or incapacity; a congenital anomaly
or birth defect in a neonate or infant born to a mother exposed to
study drug; or a significant medical event in the investigator’s
judgment.
The primary analysis was prespecified when the last enrolled
patient completed cycle 1 observation. The follow-up analysis
reported here was not prespecified.
Results
Patient population
Between 10 January 2015, and 14 April 2015, eight patients were
enrolled from six centers in Japan. One patient discontinued before
receiving treatment because her condition was considered by the
investigator to be too poor to start investigational treatment (poor
renal function, elevated blood pressure); the remaining seven
patients received study treatment and had measurable disease, and
were thus included in the tolerability, safety and efficacy analyses.
Baseline characteristics are shown in Table 1, with further details
including the selected treatment schedule provided in Supplementary
data, Table S1 (online only).
Treatment exposure
The data cutoff for the primary analysis was 7 May 2015, when the
last patient completed cycle 1 observation. We report an updated
analysis with a data cutoff of 14 October 2015. As of this date, the
median number of bevacizumab treatment cycles delivered was nine
(range 7–12). The median number of cycles of paclitaxel and cis-
platin was six (range 4–12). These medians represent 6.5 months of
bevacizumab exposure (range 5.1–8.7 months) and 3.7 months of
chemotherapy exposure (range 2.1–8.4 months). Treatment expos-
ure is summarized in Fig. 1.
Five patients continued bevacizumab as a single agent after dis-
continuation of chemotherapy. The median duration of single-agent
Table 1. Patient characteristics at baseline
Characteristic JO29569 (n = 7)
Median age, years (range) 61 (34–69)
GOG performance status, n (%)
0 6 (86)
1 1 (14)
Histologic subtype, n (%)
Squamous cell carcinoma 3 (43)
Adenocarcinomaa 2 (29)
Adenosquamous 1 (14)
Small cell carcinoma 1 (14)
Disease status, n (%)
Stage IVB 3 (43)
Recurrent 4 (57)
Persistent 0
Prior platinum therapy, n (%) 2 (29)b
Prior radiotherapy to pelvis, n (%) 3 (43)
GOG, Gynecologic Oncology Group.
aMucinous adenocarcinoma (endocervical type) in one patient, adenocar-
cinoma unspecified in one patient.
bWith concurrent chemoradiation.
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Figure 1. Summary of treatment administered by patient. *Treatment ongoing.
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bevacizumab was three cycles (range 1–8). At the time of data cut-
off, one patient had discontinued study therapy because of disease
progression. The remaining patients were still receiving at least one
component of study therapy.
Tolerability
None of the seven treated patients experienced any of the adverse
events predefined for the primary endpoint during the tolerability
evaluation period. Therefore, according to the specified primary
objective, the regimen was considered tolerable in Japanese patients.
Safety
All seven treated patients experienced at least one adverse event of
grade ≥3 intensity, including grade 4 adverse events in three patients
(43%), but there were no fatal adverse events. The most common
adverse events (all grades) were alopecia, hypertension, decreased
appetite, nausea and peripheral sensory neuropathy (Table 2). There
were no cases of fistula. The most common grade ≥3 adverse events
were hypertension, neutrophil count decreased and neutropenia;
however, only one patient experienced febrile neutropenia (Table 2).
The majority of adverse events occurred during the concurrent
chemotherapy and bevacizumab treatment phase. Among the five
patients who received single-agent bevacizumab after discontinu-
ation of chemotherapy, three experienced a grade 3 adverse event
(one case each of hypertension, proteinuria and hyponatremia).
However, these adverse events were manageable with appropriate
treatment or temporary interruption of bevacizumab. No serious
adverse events were observed after discontinuation of chemotherapy
(Supplementary data, Table S2, online only).
Apart from the three cases of grade ≥3 hypertension, one case of
grade 4 febrile neutropenia and one case of grade 3 proteinuria men-
tioned above, none of the other predefined adverse events of special
interest for bevacizumab was observed. Adverse events led to dis-
continuation of paclitaxel in five patients (71%; peripheral sensory
neuropathy in four patients; malaise and decreased appetite in one
patient) and discontinuation of cisplatin in five patients (71%;
fatigue in two patients; malaise and decreased appetite in one
patient; nausea in one patient; increased blood creatinine in one
patient) (Table 3). None of the patients discontinued bevacizumab
because of adverse events.
Bevacizumab was temporarily interrupted because of adverse
events in all seven patients. Proteinuria and hypertension each led to
temporary interruption of bevacizumab in two patients, as did grade 2
neutropenia/neutrophil count decreased and grade 2 blood creatinine
increased. Other causes of bevacizumab interruption, each occurring
in only one patient and all considered unrelated to bevacizumab,
were: grade 2 peripheral neuropathy, grade 3 hyponatremia, pyelo-
nephritis (two episodes in one patient), herpes zoster infection and
anemia. All cases resolved following bevacizumab interruption. In
five patients, the chemotherapy dose was reduced or treatment was
interrupted because of adverse events.
Two patients experienced adverse events that met the criteria for
serious adverse events (prolonging hospitalization): grade 4 febrile
neutropenia in one patient and grade 3 pyelonephritis (considered
unrelated to study treatment) in another patient.
Efficacy
The overall response rate was 86% (95% confidence interval, 42–
100%), comprising a complete response in one patient (14%) and
partial responses in five patients (71%). The remaining patient had a
best response of stable disease. Change in tumor volume from base-
line over time is shown in Fig. 2. In three patients, including the
patient with a complete response, all target legions disappeared; how-
ever, in two patients evaluation of non-target lesions did not meet the
criteria for complete response, therefore, these patients were assessed
as partial responders. Computed tomography scans from one patient
before and after bevacizumab treatment are shown in Fig. 3.
Progression-free survival results are immature as six patients
remained on treatment with sustained disease control at the time of
data cutoff.
Discussion
In this small prospective clinical study designed to assess the toler-
ability, safety and activity of bevacizumab-containing therapy in
Japanese patients with advanced or recurrent cervical cancer, the
combination of bevacizumab, cisplatin and paclitaxel was tolerable.
Generally, the safety profile was consistent with previous reports of
Japanese populations receiving bevacizumab in other disease settings
(9,10) and the safety profile observed in the bevacizumab-containing
arm of the GOG-0240 randomized Phase III trial in cervical cancer
(6). Importantly, there were no cases of fistula.
The chemotherapy schedules administered in JO29569 were
identical to the chemotherapy options available to patients in the cis-
platin plus paclitaxel arm of the GOG-0240 trial. However, in
GOG-0240, continuation of bevacizumab was not specified if
patients experienced adverse events necessitating discontinuation of
chemotherapy. In the present study, patients could continue to
receive bevacizumab as a single agent if chemotherapy was discon-
tinued because of adverse events unrelated to bevacizumab. Five of
the seven patients in JO29569 received single-agent bevacizumab
after discontinuing chemotherapy and this treatment strategy raised
no safety concerns. There is speculation in the literature about the
potential additional benefits that may be gained from maintenance
bevacizumab in cervical cancer (11). Adverse events during the
maintenance bevacizumab phase were infrequent and were manage-
able with appropriate treatment or temporary interruption of beva-
cizumab. Furthermore, as four of the six patients still receiving
treatment with sustained clinical benefit are receiving bevacizumab
as a single agent without chemotherapy, our observations seem to
lend support to the sustained disease control potentially offered by a
maintenance bevacizumab approach.
A striking difference between the population of patients enrolled
in the present study and those in GOG-0240 is their age: median
age in the Japanese study was 61 years compared with 47 years in
the Phase III trial. Only one patient in the Japanese study was aged
<55 years. This is slightly surprising given the reported preponder-
ance of younger women presenting with cervical cancer in Japan,
and may reflect some degree of selection bias for the present study.
On the other hand, all but the youngest patient in JO29569 had
GOG performance status 0 whereas in GOG-0240, almost half of
the patients had GOG performance status 1.
The median duration of study treatment was nine cycles in the
present study compared with seven cycles in patients receiving beva-
cizumab plus chemotherapy in GOG-0240. Most patients (six of
seven) were still receiving bevacizumab at the time of data cutoff for
the present report, and all of these still appeared to be deriving clin-
ical benefit, showing maintained disease stabilization, partial
response and even complete response in one patient.
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Table 2. Adverse events
Adverse event, n (%) All grades Grade 1 Grade 2 Grade 3 Grade 4
All events 7 (100) 7 (100) 7 (100) 7 (100) 3 (43)
Alopecia 7 (100) 0 7 (100) 0 0
Hypertension 6 (86) 0 3 (43) 3 (43)a 0
Decreased appetite 6 (86) 3 (43) 3 (43) 0 0
Nausea 6 (86) 4 (57) 2 (29) 0 0
Peripheral sensory neuropathy 6 (86) 3 (43) 3 (43) 0 0
Malaise 4 (57) 2 (29) 2 (29) 0 0
Dysgeusia 4 (57) 2 (29) 2 (29) 0 0
Neutrophil count decreased 3 (43) 0 1 (14) 1 (14) 1 (14)
Stomatitis 3 (43) 1 (14) 2 (29) 0 0
Upper respiratory tract infection 3 (43) 0 3 (43) 0 0
Constipation 3 (43) 1 (14) 2 (29) 0 0
Nail discoloration 3 (43) 3 (43) 0 0 0
Flushing 3 (43) 3 (43) 0 0 0
Neutropenia 2 (29) 0 0 1 (14) 1 (14)
Anemia 2 (29) 1 (14) 0 1 (14) 0
Dehydration 2 (29) 0 1 (14) 1 (14) 0
Proteinuria 2 (29) 0 1 (14) 1 (14)a 0
Blood creatinine increased 2 (29) 0 2 (29) 0 0
Vomiting 2 (29) 1 (14) 1 (14) 0 0
Fatigue 2 (29) 1 (14) 1 (14) 0 0
Back pain 2 (29) 1 (14) 1 (14) 0 0
Hemorrhoids 2 (29) 2 (29) 0 0 0
Infusion-site pain 2 (29) 2 (29) 0 0 0
Insomnia 2 (29) 2 (29) 0 0 0
Febrile neutropenia 1 (14) 0 0 0 1 (14)a
Diarrhea 1 (14) 0 0 1 (14) 0
Hyponatremia 1 (14) 0 0 1 (14) 0
Gingivitis 1 (14) 0 0 1 (14) 0
Pyelonephritis 1 (14) 0 0 1 (14) 0
Infusion-site phlebitis 1 (14) 0 1 (14) 0 0
Wound infection 1 (14) 0 1 (14) 0 0
Herpes zoster 1 (14) 0 1 (14) 0 0
Gamma glutamyltransferase increased 1 (14) 0 1 (14) 0 0
Ingrowing nail 1 (14) 0 1 (14) 0 0
Urinary tract infection 1 (14) 0 1 (14) 0 0
Weight decreased 1 (14) 0 1 (14) 0 0
Pruritus 1 (14) 1 (14) 0 0 0
Rash maculopapular 1 (14) 1 (14) 0 0 0
Abdominal pain upper 1 (14) 1 (14) 0 0 0
Infusion-site edema 1 (14) 1 (14) 0 0 0
Edema 1 (14) 1 (14) 0 0 0
Oral herpes 1 (14) 1 (14) 0 0 0
Aspartate aminotransferase increased 1 (14) 1 (14) 0 0 0
Alanine aminotransferase increased 1 (14) 1 (14) 0 0 0
Blood pressure increased 1 (14) 1 (14) 0 0 0
Arthralgia 1 (14) 1 (14) 0 0 0
Myalgia 1 (14) 1 (14) 0 0 0
Hot flush 1 (14) 1 (14) 0 0 0
Pharyngeal inflammation 1 (14) 1 (14) 0 0 0
Periodontal disease 1 (14) 1 (14) 0 0 0
Abdominal discomfort 1 (14) 1 (14) 0 0 0
Fecal incontinence 1 (14) 1 (14) 0 0 0
Chills 1 (14) 1 (14) 0 0 0
Face edema 1 (14) 1 (14) 0 0 0
Infusion-site induration 1 (14) 1 (14) 0 0 0
Infusion-site swelling 1 (14) 1 (14) 0 0 0
Edema peripheral 1 (14) 1 (14) 0 0 0
Periodontitis 1 (14) 1 (14) 0 0 0
Tinea infection 1 (14) 1 (14) 0 0 0
Headache 1 (14) 1 (14) 0 0 0
Continued
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Interestingly, no cases of fistula, including gastrointestinal-
vaginal fistula, were observed in the present study in Japanese
patients. In the GOG-0240 trial, an exploratory analysis of the
clinico-pathologic characteristics associated with development of
fistulae revealed that all of the patients who developed
gastrointestinal-vaginal fistulae had received prior pelvic irradiation
(8). In JO29569, three of the seven patients had received pelvic
irradiation. Although the lack of gastrointestinal-fistula events, even
in patients with prior pelvic irradiation, is reassuring, it is impossible
to draw firm conclusions about this particular adverse event in
Japanese patients from such a small study. In addition, these
findings should be interpreted with a degree of caution given the
duration of exposure and ongoing bevacizumab therapy in six
patients. In GOG-0240, the median time of fistula appearance was
cycle 5, and fistula events were observed as late as cycle 10 or 12 in
some patients (6).
The incidence of grade ≥2 hypertension in the present study
(86%) appears to be considerably higher than that reported in
GOG-0240 (25%). This apparent difference may be explained in
part by the different versions of the NCI CTCAE used: in GOG-
0240, adverse events were graded according to version 3.0 whereas
in the present study we used the more recent version 4.03, which
Table 2. Continued
Adverse event, n (%) All grades Grade 1 Grade 2 Grade 3 Grade 4
Dizziness 1 (14) 1 (14) 0 0 0
Cough 1 (14) 1 (14) 0 0 0
Contusion 1 (14) 1 (14) 0 0 0
Excoriation 1 (14) 1 (14) 0 0 0
Fall 1 (14) 1 (14) 0 0 0
Anxiety 1 (14) 1 (14) 0 0 0
Tinnitus 1 (14) 1 (14) 0 0 0
aAdverse event of special interest for bevacizumab.
Table 3. Summary of efficacy and reason for treatment discontinuation by patient
Patient
number
Best
overall
response
PFS,
months
Reason for treatment discontinuation
Paclitaxel Cisplatin Bevacizumab
1 PR 5.6 Grade 1 peripheral sensory neuropathy Grade 1 fatigue Disease progression
2 PR 5.4a Grade 2 peripheral sensory neuropathy Grade 1 fatigue –
3 PR 4.8a – – –
4 PR 7.6a Grade 2 peripheral sensory neuropathy Grade 2 blood creatinine increased –
5 CR 5.9a Grade 2 malaise, grade 2 decreased appetite Grade 2 malaise, grade 2 decreased appetite –
6 SD 7.4a – – –
7 PR 5.8a Grade 1 peripheral neuropathy Grade 1 nausea –
PFS, progression-free survival; PR, partial response; CR, complete response; SD, stable disease.
aCensored observation, treatment ongoing.
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has more stringent criteria for hypertension. Consistent with GOG-
0240, none of the patients treated in the present study required dis-
continuation of bevacizumab because of hypertension (or indeed
any adverse event). Interestingly, grade ≥3 thromboembolic events
were more common with bevacizumab-containing therapy than
chemotherapy alone in GOG-0240, but we observed no thrombo-
embolic events among Japanese patients treated with bevacizumab
in JO29569.
Although the safety and efficacy data in Japanese patients with
cervical cancer are limited, being based on only seven patients trea-
ted in the present study, the results reported here together with
results from the GOG-0240 trial give no reason to anticipate
unacceptable toxicity in Japanese patients receiving bevacizumab-
containing therapy for cervical cancer. Efficacy results should be
interpreted with caution, especially in a single-arm study.
Nevertheless, the 86% response rate provides a reassuring sugges-
tion of activity.
To the best of our knowledge, the only other reported data on
bevacizumab-containing therapy for cervical cancer in Japanese
patients come from a series of 12 patients treated with bevacizumab,
paclitaxel and carboplatin with or without the multikinase inhibitor
sorafenib (12). However, as the dose and schedule of both bevacizu-
mab and chemotherapy were quite different from those adminis-
tered in our study, and seven patients also received sorafenib, it is
difficult to draw any conclusion about safety from the limited data
reported.
Further investigation of bevacizumab plus chemotherapy will be
needed in Japanese patients with cervical cancer given the paucity of
data in this setting. The ongoing CECILIA study will provide add-
itional data on the tolerability and activity of bevacizumab in
populations from geographic regions other than the US and Spain,
as it is recruiting in South America, South Africa and Europe
(13). However, no sites from Asia are involved in this study.
Furthermore, the CECILIA study is designed to assess the safety of
bevacizumab not only in different geographic regions with differing
healthcare systems and standards, but also to answer the important
question concerning whether bevacizumab can be combined with a
carboplatin-based chemotherapy backbone rather than the cisplatin/
paclitaxel regimen evaluated both in GOG-0240 and in the present
Japanese study. In many countries, carboplatin may be preferred to
cisplatin. Use of a carboplatin chemotherapy backbone in Japanese
patients is supported by results of the recently published Japanese
JCOG0505 randomized phase III trial, which demonstrated non-
inferior overall survival with carboplatin plus paclitaxel versus con-
ventional cisplatin plus paclitaxel in patients with metastatic or
recurrent cervical cancer. In exploratory subgroup analyses, overall
survival was more favorable with carboplatin plus paclitaxel in
patients previously treated with platinum-containing therapy,
whereas in platinum-naïve patients, cisplatin plus paclitaxel was
associated with improved overall survival (14). To date, no safety
data are available for this alternative bevacizumab-containing regi-
men but there is no reason to expect a difference in safety profile,
particularly as a regimen of paclitaxel, carboplatin and bevacizumab
has been evaluated extensively in other tumor types including ovar-
ian cancer (15,16).
In summary, the GOG-0240 regimen of bevacizumab, cisplatin
and paclitaxel was shown to be tolerable with a predictable and
manageable safety profile in Japanese patients with advanced or
recurrent cervical cancer, albeit in a small single-arm study. The
combination of bevacizumab plus chemotherapy seems to be an
appropriate treatment option for Japanese patients with advanced
or recurrent cervical cancer.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical
Oncology online.
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